TICKERNERD
Menu
BRKRBRKRHealthcare · Medical Devices

BRKR Stock Forecast: Bruker Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$60
−0.60% on the day

The 13 Wall Street analysts covering Bruker Corp. hold a median 12-month price target of $60 — +0.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$9.1B
Ticker Nerd rank
84 / 100
Median analyst target
$60
Analysts covering
13
Total return, dividends reinvested
1W
+3.2%
1M
−1.4%
YTD
+26.7%
1Y
+77.1%
From 52W high
−7.4%
From 52W low
+104.0%
$29
$64
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BRKR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bruker Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
84 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
89
Value
84
Accruals
77
Momentum
70
Volatility
68
Quality
66
Revisions
61
Growth
57
Size
17

Issuance (89): The share count has been shrinking and the company is not leaning on new borrowing.

Growth (57): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BRKR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BRKR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26BRKRHigh $70Median $60Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says13 analysts
8 Buy4 Hold1 Sell
Low $40Median $60High $70

The green dot is the last close — the median target sits +0.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
5 Aug 2026CitigroupMaintainsNeutral$60 → $53
8 July 2026CitigroupMaintainsNeutral$44 → $60
8 July 2026CitigroupMaintainsNeutral—
7 July 2026Leerink PartnersMaintainsOutperform$60 → $70
7 July 2026Leerink PartnersMaintainsOutperform—
29 June 2026GuggenheimMaintainsBuy—
24 June 2026BarclaysMaintainsOverweight—
8 June 2026JP MorganMaintainsOverweight—
2 June 2026Wolfe ResearchAssumesPeer Perform—
7 May 2026BarclaysMaintainsOverweight—
7 May 2026CitigroupMaintainsNeutral—
7 May 2026TD CowenMaintainsHold—
7 May 2026UBSMaintainsNeutral—
15 Apr 2026BarclaysMaintainsOverweight—
14 Apr 2026BarclaysMaintainsOverweight—
30 Mar 2026GuggenheimMaintainsBuy—
13 Feb 2026BarclaysMaintainsOverweight—
13 Feb 2026CitigroupMaintainsNeutral—
13 Feb 2026Goldman SachsMaintainsSell—
13 Feb 2026TD CowenMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BRKR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BRKR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.1%
Analysts raising
5
Analysts cutting
5
Fundamentals

Bruker Corp. (BRKR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
74.9×

Cheaper than 10% of US stocks

Price / sales
2.6×

Cheaper than 46% of US stocks

Price / book
3.8×

Cheaper than 28% of US stocks

EV / EBITDA
20.0×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
5.2%

Higher than 39% of US stocks

Earnings growth (YoY)
5.2%

Higher than 42% of US stocks

Gross margin
49.6%

Higher than 62% of US stocks

Operating margin
9.9%

Higher than 64% of US stocks

Net margin
−2.0%

Higher than 27% of US stocks

Returns & dividend
Return on equity
−3.0%

Higher than 41% of US stocks

Return on assets
3.1%

Higher than 66% of US stocks

Dividend yield
0.3%

Higher than 6% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BRKR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BRKRBruker Corp.$9.1B
84
BIOBio-Rad Laboratories, Inc.$10.2B
92
PODDInsulet Corp.$10.3B
90
GKOSGlaukos Corp.$10.9B
91
GMEDGlobus Medical, Inc.$11.7B
96
PENPenumbra, Inc.$12.8B
76
HAEHaemonetics Corp.$5.1B
98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bruker Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BRKR news & analysis

Touchstone Mid Cap Fund Q2 2026 Portfolio Review

Seeking Alpha · 13 Aug 2026positive

The Touchstone Mid Cap Fund underperformed its benchmark, the Russell MidCap Index, for the quarter ended June 30, 2026. Bruker Corporation was listed among the largest contributors to the Fund's performance during this period.

Why it matters — A BRKR watcher would care because the fund review identifies Bruker as one of the top performers driving fund results during the quarter, signaling relative strength among mid-cap holdings.

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

Business Wire · 11 Aug 2026positive

Bruker announced an expanded strategic collaboration with Atinary Technologies, a developer of Self-Driving Labs and AI-driven R&D technologies, and made a minority investment in the company. Financial details were not disclosed. Atinary intends to integrate Chemspeed laboratory automation platforms, Bruker analytical instruments, and SciY software.

Why it matters — A Bruker watcher would care because the expanded partnership and minority stake signal deeper integration of Bruker instruments and software into AI-driven self-driving laboratory offerings, potentially broadening its reach in pharma, chemicals, energy, and materials.

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

Business Wire · 10 Aug 2026positive

Bruker Corporation announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and human tissue and disease models. The investment expands Bruker's post-genomic offerings for disease biology research and drug discovery into Microphysiological Systems (MPS) based on human physiology.

Why it matters — This move broadens Bruker's portfolio into human-physiology-relevant drug discovery and development tools, adding a new growth area in microphysiological systems for BRKR watchers.

Carillon Chartwell Mid Cap Value Fund Q2 2026 Portfolio Review

Seeking Alpha · 5 Aug 2026neutral

Carillon Chartwell Mid Cap Value Fund published its Q2 2026 portfolio review. The review discusses holdings including ON Semiconductor, Knight-Swift Transportation, and Expand Energy, with no mention of Bruker Corp.

Why it matters — The item contains no information about Bruker Corp., so it offers no relevant insight for BRKR watchers.

Bruker Corporation (BRKR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

Bruker Corporation (BRKR) held its Q2 2026 earnings call, and the full transcript of that call was published by Seeking Alpha. The item provides the company's second-quarter 2026 earnings call transcript.

Why it matters — BRKR watchers would care because the transcript offers direct access to management's discussion of the company's Q2 2026 financial results and outlook.

FAQ

Frequently asked questions about BRKR stock

What is the BRKR stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Bruker Corp. have a median 12-month price target of $60, with estimates ranging from $40 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BRKR stock a buy right now?

Of the 13 analysts covering Bruker Corp., 8 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bruker Corp. 84 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BRKR?

As at 22 Aug 2026, Bruker Corp. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (89 of 100).

Will BRKR stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +0.7% from the last close, and Ticker Nerd's factor model ranks Bruker Corp. 84 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BRKR stock forecast for 2030?

No analyst covering Bruker Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BRKR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $70 over the next 12 months.

How has BRKR stock performed over the past year?

Bruker Corp. returned +77.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bruker Corp. do?

Bruker Corporation is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions that enable molecular and materials research across academic, governmental, and industrial laboratories worldwide. The company designs and distributes nuclear magnetic resonance spectrometers, mass spectrometry platforms, X-ray diffraction instruments, atomic force microscopes, and preclinical imaging systems such as micro-CT and MRI scanners.

What is the latest news on BRKR?

The most recent item we track (Seeking Alpha, 13 Aug 2026): "Touchstone Mid Cap Fund Q2 2026 Portfolio Review". The Touchstone Mid Cap Fund underperformed its benchmark, the Russell MidCap Index, for the quarter ended June 30, 2026. Bruker Corporation was listed among the largest contributors to the Fund's performance during this period.

Company

About Bruker Corp.

Bruker Corporation is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions that enable molecular and materials research across academic, governmental, and industrial laboratories worldwide. The company designs and distributes nuclear magnetic resonance spectrometers, mass spectrometry platforms, X-ray diffraction instruments, atomic force microscopes, and preclinical imaging systems such as micro-CT and MRI scanners. In addition to hardware, Bruker provides comprehensive software suites, applications support, training services, and long-term maintenance agreements to optimize instrument performance. The company serves diverse customer segments in the pharmaceutical, biotechnology, chemical, semiconductor, energy, and environmental sectors through four primary business segments: Bruker Scientific Instruments BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. With research and development, manufacturing, and service centers located throughout the Americas, Europe, and Asia, Bruker maintains a global infrastructure to support its worldwide customer base. Founded in 1960 and headquartered in Billerica, Massachusetts, the company continues to play a significant role in advancing scientific research and analysis globally.

CEO Dr. Frank H. Laukien Ph.D. · 11,085 employees · United States · https://www.bruker.com